Background: The aim of the present study was to describe an unselected population of patients with diagnosis of FIGO stage IV OC. Methods: Data from 1183 patients were available for analysis. Results: The majority of patients (962/1183, 81.3%) received cancer-directed treatment. The median follow-up time was 3.8 years, and the median overall survival duration was 1.9 years. Notably, patients >80 years had a low overall survival rate (HR of age >80 years vs. ≤50 years was 3.81, 95%-CI [2.76, 5.27],p< 0.0001). The survival rate was best in patients with HGSOC (p< 0.0001). The highest overall survival rate was observed in patients in the group with surgical intervention followed by systemic treatment, with an unadjusted HR of 0.72, 95%-CI [0.59, 0.86],p= 0.007 vs. systemic treatment only. After adjustment for age and histology, survival differences between treatment schemes were smaller (HR 0.81, 95%-CI [0.66, 1.00],p= 0.12). Conclusions: In this cohort of patients with FIGO stage IV OC, more than 80% of the patients received cancer-directed treatment. Age and high-grade serous histology were determinants for survival. The highest overall survival rate was observed in patients who underwent surgery followed by systemic treatment.
背景：本研究旨在描述一组未经筛选的FIGO IV期卵巢癌患者群体。方法：共纳入1183例患者数据进行分析。结果：大多数患者（962/1183，81.3%）接受了肿瘤针对性治疗。中位随访时间为3.8年，中位总生存期为1.9年。值得注意的是，80岁以上患者总生存率较低（年龄>80岁与≤50岁的风险比为3.81，95%置信区间[2.76, 5.27]，p<0.0001）。高级别浆液性癌患者生存率最佳（p<0.0001）。接受手术联合全身治疗的患者组总生存率最高，与单纯全身治疗组相比，未经校正的风险比为0.72（95%置信区间[0.59, 0.86]，p=0.007）。经年龄和组织学类型校正后，不同治疗方案间的生存差异缩小（风险比0.81，95%置信区间[0.66, 1.00]，p=0.12）。结论：在本FIGO IV期卵巢癌患者队列中，超过80%的患者接受了肿瘤针对性治疗。年龄和高级别浆液性组织学类型是生存的决定因素。手术联合全身治疗患者的总体生存率最高。
肿瘤(癌症)患者之家